Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of Nivolumab in Combination With Tocilizumab for Treatment of Patients With Relapsed Hematological Malignancies Post-allogeneic Transplant

NCT03588936 is registered in ClinicalTrials.gov with Medical College of Wisconsin as lead sponsor.

NCT NCT03588936
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03588936 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of Nivolumab in Combination With Tocilizumab for Treatment of Patients With Relapsed Hematological Malignancies Post-allogeneic Transplant
Lead sponsor
Medical College of Wisconsin
Phase
Phase 1
Overall status
Terminated
Start date
September 14, 2018
Completion date
July 15, 2020
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia, chronic leukemia, lymphoma, myelodysplastic syndromes